ATE146076T1 - Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten - Google Patents

Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten

Info

Publication number: ATE146076T1
Authority: AT; Austria
Prior art keywords: treatment; receptor antagonists; chronic kidney; imidazole; kidney failure
Prior art date: 1990-06-22

Application number

AT91912884T

Other languages

English (en)

Inventor

David John Carini

John Jonas Vytautas Duncia

Pancras Chor-Bun Wong

Original Assignee

Du Pont

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-22

Filing date

1991-06-07

Publication date

1996-12-15

1991-06-07 Application filed by Du Pont filed Critical Du Pont

1996-12-15 Application granted granted Critical

1996-12-15 Publication of ATE146076T1 publication Critical patent/ATE146076T1/de

Links

208000020832 chronic kidney disease Diseases 0.000 title abstract 2
208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 title 1
239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
UUPNFNCKGJOLQE-UHFFFAOYSA-N 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 UUPNFNCKGJOLQE-UHFFFAOYSA-N 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
150000002460 imidazoles Chemical class 0.000 abstract 1
PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT91912884T 1990-06-22 1991-06-07 Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten ATE146076T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US54235190A	1990-06-22	1990-06-22

Publications (1)

Publication Number	Publication Date
ATE146076T1 true ATE146076T1 (de)	1996-12-15

Family

ID=24163446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91912884T ATE146076T1 (de)	1990-06-22	1991-06-07	Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten

Country Status (8)

Country	Link
EP (1)	EP0533840B1 (de)
JP (2)	JPH05509086A (de)
AT (1)	ATE146076T1 (de)
CA (1)	CA2085584C (de)
DE (1)	DE69123582T2 (de)
DK (1)	DK0533840T3 (de)
GR (1)	GR3022035T3 (de)
WO (1)	WO1992000067A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2058198A1 (en) *	1991-01-04	1992-07-05	Adalbert Wagner	Azole derivatives, process for their preparation, and their use
JP3810020B2 (ja) *	1993-04-22	2006-08-16	武田薬品工業株式会社	腎疾患の予防または治療剤
FR2719598B1 (fr) *	1994-05-03	1996-07-26	Rhone Poulenc Chimie	Composition élastomère silicone et ses applications, notamment pour l'enduction de sac gonflable, destiné à la protection d'un occupant de véhicule.
AU677702B2 (en) *	1994-10-13	1997-05-01	Takeda Pharmaceutical Company Limited	A prophylactic or therapeutic drug for renal diseases
US6498142B1 (en) *	1996-05-06	2002-12-24	Curis, Inc.	Morphogen treatment for chronic renal failure
AU743510B2 (en)	1997-05-05	2002-01-24	Stryker Corporation	Therapies for acute renal failure
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
AU2002241966A1 (en)	2001-01-26	2002-08-28	Chugai Seiyaku Kabushiki Kaisha	Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2002058690A2 (en)	2001-01-26	2002-08-01	Chugai Seiyaku Kabushiki Kaisha	Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
ATE509014T1 (de)	2001-01-26	2011-05-15	Chugai Pharmaceutical Co Ltd	Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
NZ526883A (en)	2001-02-20	2005-11-25	Chugai Pharmaceutical Co Ltd	Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US7709510B2 (en)	2001-02-20	2010-05-04	Chugai Seiyaku Kabushiki Kaisha	Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
JP4727579B2 (ja)	2003-08-01	2011-07-20	中外製薬株式会社	マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なシアノアミド化合物
JP4648317B2 (ja)	2003-08-01	2011-03-09	中外製薬株式会社	マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用なピペリジン化合物
ATE487475T1 (de)	2003-08-01	2010-11-15	Chugai Pharmaceutical Co Ltd	Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
WO2005037258A2 (en)	2003-08-01	2005-04-28	Chugai Seiyaku Kabushiki Kaisha	Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
US8257797B2 (en)	2003-11-03	2012-09-04	Bluestar Silicones France	Silicone composition and process that is useful for improving the tear strength and the combing strength of an inflatable bag for protecting an occupant of a vehicle
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011518884A (ja) *	2008-04-29	2011-06-30	セラヴァンス，インコーポレーテッド	二重活性抗高血圧剤
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20120264753A1 (en) *	2009-12-22	2012-10-18	Kowa Company, Ltd.	Novel 1-(biphenyl-4-yl-methyl)-1h-imidazole derivative and pharmaceutical product containing same
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP2968439A2 (de)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Zusammensetzungen zur behandlung von magen-darm-störungen
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
BR112018077075A2 (pt)	2016-06-29	2019-04-30	Universite De Montreal	heterociclos de biarilmetila

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
SG52330A1 (en) *	1989-06-14	1998-09-28	Smithkline Beecham Corp	Imidazolyl-alkenoic acids
KR0163595B1 (ko) *	1989-06-30	1998-12-01	미리암디, 메코너헤이	치환된 이미다졸
CA2032289A1 (en) *	1989-12-29	1991-06-30	Joseph A. Finkelstein	Substituted 5-(alkyl) carboxamide imidazoles

1991
- 1991-06-07 AT AT91912884T patent/ATE146076T1/de not_active IP Right Cessation
- 1991-06-07 EP EP91912884A patent/EP0533840B1/de not_active Expired - Lifetime
- 1991-06-07 CA CA002085584A patent/CA2085584C/en not_active Expired - Lifetime
- 1991-06-07 WO PCT/US1991/003906 patent/WO1992000067A2/en not_active Ceased
- 1991-06-07 DK DK91912884.3T patent/DK0533840T3/da active
- 1991-06-07 JP JP3512070A patent/JPH05509086A/ja active Pending
- 1991-06-07 DE DE69123582T patent/DE69123582T2/de not_active Expired - Lifetime
1996
- 1996-12-13 GR GR960403462T patent/GR3022035T3/el unknown
1998
- 1998-11-12 JP JP10321761A patent/JPH11228410A/ja active Pending

Also Published As

Publication number	Publication date
CA2085584A1 (en)	1991-12-23
CA2085584C (en)	2003-02-11
GR3022035T3 (en)	1997-03-31
EP0533840A1 (de)	1993-03-31
DE69123582D1 (de)	1997-01-23
WO1992000067A2 (en)	1992-01-09
JPH11228410A (ja)	1999-08-24
DK0533840T3 (da)	1996-12-30
WO1992000067A3 (en)	1993-05-27
EP0533840B1 (de)	1996-12-11
DE69123582T2 (de)	1997-05-15
JPH05509086A (ja)	1993-12-16

Legal Events

Date	Code	Title	Description
2011-09-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
DE69123582D1 (de)	1997-01-23	Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
EP0803252A3 (de)	1997-11-26	Behandlung der Schädigung des Zentralnervensystems mit Imidazolangiotensin-II-Rezeptor-Antagonisten
NO1995004I1 (no)	1995-05-26	Losartan/ 2-butyl-4-klor-1-((2'-(1H-tetrazol-5-yl)-bifenyl-4-yl)-metyl)-5-(hydroksylmetyl)-imidazol
DE69413523D1 (de)	1998-10-29	Benzimidazole derivate
ATE103604T1 (de)	1994-04-15	Substituierte 5-((tetrazolyl)alkenyl>-imidazole.
MX9204737A (es)	1994-02-28	Acidos imidazolil-alquenoicos
ATE134368T1 (de)	1996-03-15	Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
ATE371645T1 (de)	2007-09-15	Naphthalinderivate, die sich an den ep4?rezeptor binden
DE68907921D1 (de)	1993-09-09	Substituierte pyrrol-, pyrazol- und triazol-angiotensin ii-antagonisten.
DK0403159T3 (da)	2000-08-14	Imidazolylalkensyrer
AR006439A1 (es)	1999-08-25	Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
BR9708517A (pt)	1999-08-03	Composição farmacêutica processo para prevenir ou tratar doenças mediadas por angiotensina ii em um mamífero e uso de um composto
KR920006323A (ko)	1992-04-27	아자사이클릭 화합물
DK0831911T3 (da)	2002-07-22	Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
NO972324D0 (no)	1997-05-21	Orale blandinger inneholdende Ondansetron
WO2006101521A3 (en)	2006-12-28	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BR9104918A (pt)	1992-06-23	Utilizacao de compostos bloqueadores do receptor de angiotensina-ii,processo para o tratamento da hipertrofia e/ou hiperplasia cardial e vascular,processo para a obtencao de um preparo farmaceutico e composicao farmaceutica
DK1175902T3 (da)	2005-12-19	Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
ATE353875T1 (de)	2007-03-15	Indolderivate
NO904799D0 (no)	1990-11-05	Substituerte n-(imidazolyl)alkylalanin-derivater.
TR200102107T2 (tr)	2001-12-21	Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
TR199701536T1 (xx)	1998-02-21	Benzimidazollerin, l�seminin tedavisi i�in bir ila� �retilmesinde kullan�m�.
ES2184892T3 (es)	2003-04-16	Antagonistas del receptor at1 para prevenir y tratar la insuficiencia renal postisquemica y para proteger los riñones isquemicos.
DK1019048T3 (da)	2004-05-03	Anvendelse af en angiotensin II-reseptorantagonist til fremstilling af lægemidler til forøgelse af overlevelsesfrekvensen af nyretransplanterede patienter
ES2182334T3 (es)	2003-03-01	Monohidrato de eprosartan.